spacer
home > ebr > autumn 2007 > the protein production line
PUBLICATIONS
European Biopharmaceutical Review

The Protein Production Line

Clemens Achmüller and Bernhard Auer at the Austrian Center of Biopharmaceutical Technology, Institute of Biochemistry, University of Innsbruck, Austria investigate fusion protein technology for expression of therapeutic proteins and peptides in E coli

The production of therapeutic proteins requires rapid, efficient and cost effective expression and purification strategies. Moreover, the design of such strategies has to be developed for each protein or peptide individually. More generally, applicable expression systems, which are not driven by the individual protein, would substantially reduce the time for product development. Fusion protein technology represents one way to achieve these goals, by enhancing protein expression, reducing protein degradation, assisting proper folding, facilitatating purification and, in some cases, generating protein with a native N-terminus. Hence, protein fusion techniques are a primary option to manufacture therapeutic proteins and peptides, especially in E coli, which is still a widely-used host in industrial scale production. This review covers recent developments in protein fusions for periplasmic expression and expression in the cytoplasm in soluble form. Further focus will be on the production of fusion proteins in inclusion bodies and a newly developed method of autoprotease fusion technology.

In the production of biopharmaceuticals, E coli has been the longstanding workhorse due to its simplicity, low cost and high productivity. Only the need for specific modification of proteins (such as glycosylation) has driven researchers and production facilities towards more costly higher organisms like baculovirus and mammalian cell culture systems. A major problem in reducing the costs for product development in the pharmaceutical industry is the invariably long time and high cost of clinical testing and evaluation of efficacy of the drug.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Clemens Achmüller gained his PhD from the University of Innsbruck with work on the development of protein expression systems, based on viral autoproteases in 2006 (with Bernhard Auer). He is now a postdoctoral fellow in the Institute of Biochemistry at Innsbruck.

Bernhard Auer has been a Chemist and Professor of Biochemistry at the University of Innsbruck, Austria, since 1988. Starting from E coli phage genetics he worked for about two decades on DNA-repair processes in mammalian cells. Around 2000 he returned to the E coli system where he now focuses on protein expression systems.

spacer
Clemens Achmüller
spacer
spacer
spacer
Bernhard Auer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ADM Supports Clinical Trial into Effects of Probiotic Supplements for COVID-19 Patients in Hospital Care

ADM and Hospital de Sagunto, one of the largest medical centers in the Valencia region, today announce their partnership for a clinical trial into the effects of using a food supplement containing live microbial strains to promote gut microbiome balance and help improve health functions related to outcomes for COVID-19 patients in high-risk groups. On 18th March Dr Xavier Cortés, gastroenterologist at Hospital de Sagunto, communicated with medical staff in China who had observed that many COVID-19 patients had exhibited abnormal changes in their gut microbiome.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement